Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Capital Leases (2021 - 2025)

Verrica Pharmaceuticals has reported Capital Leases over the past 5 years, most recently at $643000.0 for Q4 2025.

  • Quarterly results put Capital Leases at $643000.0 for Q4 2025, down 16.28% from a year ago — trailing twelve months through Dec 2025 was $643000.0 (down 16.28% YoY), and the annual figure for FY2025 was $643000.0, down 16.28%.
  • Capital Leases for Q4 2025 was $643000.0 at Verrica Pharmaceuticals, up from $629000.0 in the prior quarter.
  • Over the last five years, Capital Leases for VRCA hit a ceiling of $2.0 million in Q3 2024 and a floor of $13000.0 in Q2 2022.
  • Median Capital Leases over the past 5 years was $629000.0 (2025), compared with a mean of $664600.0.
  • Biggest five-year swings in Capital Leases: skyrocketed 2346.91% in 2024 and later tumbled 68.26% in 2025.
  • Verrica Pharmaceuticals' Capital Leases stood at $16000.0 in 2021, then decreased by 18.75% to $13000.0 in 2022, then surged by 7792.31% to $1.0 million in 2023, then fell by 25.15% to $768000.0 in 2024, then dropped by 16.28% to $643000.0 in 2025.
  • The last three reported values for Capital Leases were $643000.0 (Q4 2025), $629000.0 (Q3 2025), and $579000.0 (Q2 2025) per Business Quant data.